Bastiano Sanna - Apr 4, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 4, 2023
Transactions value $
-$164,854
Form type
4
Date filed
4/6/2023, 04:23 PM
Previous filing
Apr 4, 2023
Next filing
Apr 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$66.3K -211 -0.44% $314.22 47.6K Apr 4, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$29.7K -94 -0.2% $315.66 47.5K Apr 4, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$28.5K -90 -0.19% $316.76 47.4K Apr 4, 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale -$30.5K -96 -0.2% $317.65 47.3K Apr 4, 2023 Direct F1, F2, F6
transaction VRTX Common Stock Sale -$9.88K -31 -0.07% $318.68 47.3K Apr 4, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $314.22 (range $313.72 to $314.70).
F4 Open market sales reported on this line occurred at a weighted average price of $315.66 (range $315.08 to $315.96).
F5 Open market sales reported on this line occurred at a weighted average price of $316.76 (range $316.41 to $317.20).
F6 Open market sales reported on this line occurred at a weighted average price of $317.65 (range $317.49 to $317.74).